By integrating phenotypic assays with transcriptomic profiling, distinct downstream effectors were revealed—including TRAF2 and LOXL2—that connect TFAM dysregulation to cell cycle control, metabolic reprogramming, and tumor invasiveness. The gene discussed is LOXL2; the disease is neoplasm.